As of Nov 19, 2026, 0 of 2 active firms rate PACB a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PACB EPS & revenue forecast
EPS · NEXT QUARTER
$-0.10
Range $-0.13 – $-0.09 · 6 analysts · -15% YoY
Next period, 6 analysts expect Pacific Biosciences of California to earn $-0.10 a share (range $-0.13 – $-0.09), versus $-0.12 a year earlier. Full-year consensus is $-0.49, growing to $-0.40 the year after.
REVENUE · NEXT QUARTER
$40.6M
Range $38.8M – $42.3M · 6 analysts · +9% YoY
Revenue is expected to reach $40.6M (range $38.8M – $42.3M), +9.2% year-over-year. Full-year consensus is $157.5M, rising to $178.1M next year.
Top analysts covering Pacific Biosciences of California
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PACB.
#1
MC
Mason Carrico
Stephens & Co. · Rank #178
Buy
$2.50+36.2% to target
Overall win rate
40%
+ Follow
#2
SJ
Sung Ji Nam
Scotiabank · Rank #186
Buy
$2.00+9.0% to target
Overall win rate
47%
+ Follow
#3
KM
Kyle Mikson
Canaccord Genuity · Rank #202
Buy
$3.00+63.5% to target
Overall win rate
40%
+ Follow
#4
Luke Sergott
Barclays · Rank #267
Sell
$1.25-31.9% to target
Overall win rate
43%
+ Follow
#5
David Westenberg
Piper Sandler · Rank #314
Neutral
$2.00+9.0% to target
Overall win rate
35%
+ Follow
PACB stock forecast FAQ
What is PACB's average 12-month price target?+
The 2 active firms with a live target average $1.43 for Pacific Biosciences of California over the next 12 months, ranging from a $1.50 high to a $1.35 low, as of Nov 19, 2026.
Is PACB stock a Buy, Sell or Neutral right now?+
The current consensus is Insufficient coverage. Of the 2 active firms as of Nov 19, 2026, 0 rate it Buy or Strong Buy, 1 rate it Neutral, and 1 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PACB?+
The Street-high target is $1.50 (Barclays), and the Street-low is $1.35 (UBS). The average of all 2 active-firm targets is $1.43.
How many active Wall Street firms cover PACB?+
2 active firms have a recognized rating on Pacific Biosciences of California as of Nov 19, 2026, and 2 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PACB?+
Among analysts who currently cover PACB, Mason Carrico of Stephens & Co. has the strongest overall Quantellect track record (Rank #178). Their current call is Buy with a $2.50 target.
What is Pacific Biosciences of California's projected EPS for next quarter?+
The consensus estimate is $-0.10 per share (range $-0.13 – $-0.09) across 6 analysts. Full-year EPS is projected at $-0.49, rising to $-0.40 the following year.
How much revenue is Pacific Biosciences of California expected to report next quarter?+
Consensus revenue is $40.6M (range $38.8M – $42.3M). Full-year revenue is projected at $157.5M, growing to $178.1M next year.
Have analysts been upgrading or downgrading PACB lately?+
As of Nov 19, 2026, 0 of 2 active firms rate PACB a Buy (1 Neutral, 1 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PACB calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.